WO2014125977A1 - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- WO2014125977A1 WO2014125977A1 PCT/JP2014/052676 JP2014052676W WO2014125977A1 WO 2014125977 A1 WO2014125977 A1 WO 2014125977A1 JP 2014052676 W JP2014052676 W JP 2014052676W WO 2014125977 A1 WO2014125977 A1 WO 2014125977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral
- composition
- bacteria
- ascorbic acid
- oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Definitions
- the present invention has an excellent bactericidal effect against oral bacteria, particularly porphyromonas gingivalis, a periodontal disease-causing bacterium, and an oral cytostatic effect, and is effective in preventing and treating periodontal disease.
- the present invention relates to an oral composition.
- Periodontal disease is an infection caused by bacteria, mainly anaerobic gram-negative bacteria such as Porphyromonas gingivalis, and exotoxins (such as leukotoxin) and endotoxins (such as lipopolysaccharide) produced by the bacteria. ) Induces inflammation and damages the tissue.
- exotoxins such as leukotoxin
- endotoxins such as lipopolysaccharide
- human defensin a host-derived peptide
- Patent Document 1 Japanese Patent Laid-Open No. 2001-288105
- human ⁇ -defensin has a strong antibacterial activity against a periodontitis-causing fungus, Actinobacillus actinomycetemcomitans, and Porphyromonas gingivalis
- periodontitis-causing bacteria such as (Porphyromonas gingivalis) also have antibacterial activity, and a human ⁇ -defensin-containing dentifrice has been proposed.
- Patent Document 2 Japanese Patent Laid-Open No. 2009-155214 proposes a composition for oral cavity in which the antibacterial effect of oral biofilm is improved by using human defensin and dextranase in combination.
- human defensins cannot be said to have a sufficient bactericidal effect on periodontopathic bacteria, and improvement of bactericidal power has been a problem.
- ascorbic acid esters such as ascorbic acid phosphates or salts thereof eliminate excess active oxygen produced in the living body and protect the living tissue from oxidative stress injury. Although it is known that it suppresses inflammation and has an effect of inhibiting the damage of oral cells, the effect of inhibiting the cytotoxicity still has room for improvement. In addition, ascorbic acid ester or a salt thereof does not have a bactericidal effect on periodontal disease-causing bacteria.
- the present invention has been made in view of the above circumstances, and has an excellent bactericidal effect against oral bacteria, especially periodontal disease-causing bacteria and oral cell injury-suppressing effect, and is effective for the prevention and treatment of periodontal disease.
- the purpose is to provide goods.
- human defensin which is a peptide derived from the host, has antibacterial activity against periodontal disease-causing bacteria and is known as a safe component to the human body.
- P. of periodontal disease-causing bacteria g It was found that there is a problem that there is not enough bactericidal effect against bacteria.
- the oral bacterial bactericidal effect of human defensin is not sufficient, the cytotoxicity-inhibiting effect is not observed, and the cytotoxicity-inhibiting effect of ascorbic acid ester or its salt is not sufficient.
- the combination system of (A) and (B) It was able to enhance the bactericidal effect of oral bacteria and the effect of suppressing cytotoxicity beyond the additive effect of the single compound system.
- the present invention provides the following oral composition.
- An oral composition comprising (A) human defensin and (B) an ascorbic acid ester or a salt thereof.
- oral bacteria particularly P. g. It is possible to provide a composition for oral cavity containing human defensin which is excellent in bactericidal effect against bacteria and suppressive effect on cell damage in the oral cavity, is safe for the human body, and is effective for prevention and treatment of periodontal disease.
- composition for oral cavity of the present invention is characterized in that (A) human defensin and (B) ascorbic acid ester or a salt thereof are used in combination. The effect and the cytotoxic effect are improved.
- Human defensin includes human defensin ⁇ , human defensin ⁇ -1, human defensin ⁇ -2, and human defensin ⁇ -3, and one or more types selected from these are used.
- human defensin ⁇ -2 and human defensin ⁇ -3 are particularly preferable in terms of the bactericidal effect of periodontal disease-causing bacteria.
- a commercially available human defensin can be used, and examples thereof include human defensin ⁇ -2 manufactured by Peptide Institute, and human defensin ⁇ -3 manufactured by Anygen.
- the blending amount of human defensin is preferably 0.000005 to 0.0005% (mass%, the same applies hereinafter) of the whole composition, and more preferably 0.00005 to 0.0005%.
- the blending amount increases, the bactericidal effect on oral bacteria and the effect of inhibiting cell damage are improved, and blending 0.000005% or more is suitable for effect expression.
- the amount is too large, not only can the effect not be improved any longer, but there may be a case where the taste is lowered and the feeling of use may be lowered, and 0.0005% or less is suitable for securing a good feeling of use. It is.
- Ascorbic acid ester of component (B), one or more of hydroxyl groups at any of positions 2, 3, 5, and 6 of ascorbic acid is phosphoric acid, polyphosphoric acid, sulfuric acid, fatty acid, or other pharmaceutically acceptable. This is an ester of a compound.
- As the ascorbic acid ester or a salt thereof an ascorbic acid phosphate or a salt thereof, or an ascorbic acid sulfate or a salt thereof is particularly preferable.
- Ascorbic acid phosphoric acid ester and ascorbic acid sulfuric acid ester are phosphoric acid compounds such as phosphoric acid and polyphosphoric acid, or an ester of sulfuric acid.
- ascorbic acid-2-phosphate ascorbic acid-3-phosphate, ascorbic acid-6-phosphate, ascorbic acid-2-polyphosphate, ascorbic acid -2-Sulfate ester.
- the salt include alkali metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and alkaline earth metal salts.
- the component (B) one or more selected from these can be used. Particularly, it is used for the oral cavity, and is an ascorbic acid phosphate ester from the viewpoint of a gingivitis preventing effect, particularly a cytotoxicity suppressing effect.
- the magnesium salt and sodium salt are preferably used.
- the amount of ascorbic acid ester or salt thereof is preferably 0.1 to 2%, more preferably 0.2 to 1% of the total composition. As the amount is increased, the bactericidal effect on oral bacteria and the effect of suppressing cytotoxicity are improved, and it is preferable to add 0.1% or more to improve the oral bacterial sterilizing effect and the effect of suppressing cytotoxicity. Moreover, 2% or less is suitable for improving the bactericidal effect of oral bacteria and ensuring a good feeling of use. If too much is added, the bactericidal effect of oral bacteria may be reduced. Moreover, a nasty taste may appear and a feeling of use may be reduced.
- (A) ascorbic acid ester or a salt thereof (B) is preferably 20 times or more, particularly 200 to 400,000 times, more preferably 400 to 400 times by mass with respect to human defensin. 200,000 times the amount, more preferably 1,000 to 100,000 times the amount, and particularly preferably 1,000 to 10,000 times the amount. When blended in such a ratio, the effect of the present invention is further improved. To do.
- the oral composition of the present invention can be produced by adopting conventional methods for various dosage forms such as toothpaste, toothpaste such as toothpaste, liquid toothpaste, liquid toothpaste, and toothpaste, and mouthwash. Especially suitable for dentifrice.
- appropriate known components can be blended in addition to the above components as long as the effects of the present invention are not hindered.
- dentifrices contain abrasives, thickeners, binders, surfactants, and if necessary, flavors, sweeteners, colorants, preservatives, active ingredients, and the like.
- silica-based abrasives such as silica gel, precipitated silica, aluminosilicate, zirconosilicate, dicalcium phosphate dihydrate and anhydrous, tricalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, calcium carbonate, water
- examples thereof include aluminum oxide, alumina, magnesium carbonate, tribasic magnesium phosphate, zeolite, hydroxyapatite, and synthetic resin abrasive.
- the blending amount of the abrasive is adjusted depending on the dosage form, and is preferably 2 to 40%, particularly 10 to 30% for toothpaste, and 0% for liquid toothpaste.
- the thickener examples include sugar alcohols such as sorbit, xylit, malt, and lactite, and polyhydric alcohols such as glycerin, propylene glycol, and polyethylene glycol.
- the blending amount is usually 5 to 50%, particularly 20 to 45%. preferable.
- binder examples include cellulose derivatives such as sodium carboxymethyl cellulose, methyl cellulose, and hydroxyethyl cellulose, gums such as xanthan gum and gum arabic, organic binders such as carrageenan, polyvinyl alcohol, and sodium polyacrylate, gelling silica, gel Inorganic binders such as curable aluminum silica, bee gum, and laponite.
- the blending amount is usually 0.1 to 5% for toothpaste and 0 to 5% for liquid toothpaste and mouthwash.
- an anionic surfactant As the surfactant, an anionic surfactant, a nonionic surfactant, a cationic surfactant, and an amphoteric surfactant can be blended.
- the anionic surfactant include alkyl sulfates such as sodium lauryl sulfate, N-acyl sarcosine salts such as N-lauroyl sarcosine sodium and N-myristoyl sarcosine sodium, N-acyl glutamates such as sodium N-palmitoyl glutamate, Examples include sodium N-methyl-N-acyl taurine, sodium N-methyl-N-acylalanine, sodium ⁇ -olefin sulfonate, and the like.
- Nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters and maltose fatty acid esters, sugar alcohol fatty acid esters such as maltitol fatty acid esters and lactitol fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, hexaglyceryl monolaurate, Polyglycerin fatty acid esters such as hexaglyceryl monomyristate, decaglyceryl monolaurate, decaglyceryl monomyristic acid, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene Polyoxyethylene fatty acid esters such as hydrogenated castor oil and polyoxyethylene higher alcohols such as polyoxyethylene lauryl ether Ethers, fatty acid alkanolamides, such as lauric acid diethanolamide, polyoxyethylene polyoxypropylene copo
- Examples of the cationic surfactant include alkyl ammonium and alkyl benzyl ammonium salts, and examples of the amphoteric surfactant include betaines such as alkyl betaines, fatty acid amidopropyl betaines, and alkyl imidazolinium betaines.
- the blending amount of the surfactant is preferably 0.001 to 10%, particularly preferably 0.1 to 5% of the entire composition.
- Perfumes include peppermint oil, spearmint oil, anise oil, eucalyptus oil, winter green oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, Lime oil, lavender oil, rosemary oil, laurel oil, camomil oil, caraway oil, marjoram oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie Natural fragrances such as oil, coconut oil, Iris concrete, absolute peppermint, absolute rose, orange flower, and processing of these natural fragrances (front reservoir cut, rear reservoir cut, fractional distillation, liquid-liquid extraction, essence, Powdered fragrance etc.) and menthol Carvone, Anethole, Cineol, Methyl salicylate, Synamic aldehyde, Eugenol, 3-l-Mentoxypropane
- the blending amount is not particularly limited, but the above fragrance material is preferably used at 0.000001 to 1% in the preparation composition. Further, as the flavoring fragrance using the fragrance material, it is preferable to use 0.1 to 2% in the preparation composition.
- sweetener examples include saccharin sodium, stevioside, paramethoxycinnamic aldehyde, perilartin and the like.
- colorant examples include blue No. 1, yellow No. 4, titanium dioxide and the like.
- preservative examples include benzoic acid such as paraoxybenzoic acid ester and sodium benzoate, or a salt thereof.
- Active ingredients include those other than human defensin and ascorbic acid esters and salts thereof, for example, nonionic fungicides such as isopropylmethylphenol, cationic fungicides such as cetylpyridinium chloride, chlorhexidine hydrochloride, benzalkonium chloride, and benzethonium chloride , Tranexamic acid, epsilon aminocaproic acid, allantoin, glycyrrhetinic acid, glycyrrhizic acid and other anti-inflammatory agents, dextranase, mutanase, amylase, protease and other enzymes, sodium fluoride, sodium monofluorophosphate fluoride, positive phosphorus Water-soluble phosphate compounds such as potassium salts of sodium and sodium salts, copper compounds such as copper gluconate and copper chlorophyllin sodium, sodium chloride, potassium nitrate, aluminum lactate, zinc chloride, zinc citrate, Inorgan
- Examples and Comparative Examples A sample solution having the composition shown in Table 1 was prepared by a conventional method, and the cytotoxicity-inhibiting effect and the oral bacterial bactericidal effect were evaluated by the methods shown in the following experimental examples. The results are shown in the table.
- a 1 mM hydrogen peroxide aqueous solution (assuming active oxygen) was added for 60 minutes.
- the sample solution was removed, and 400 ⁇ L of a solution containing 1 mM hydrogen peroxide (D-MEM containing 10% FBS) was added and treated for 60 minutes.
- Cytotoxicity inhibition rate is 90% or more.
- O Cytotoxicity inhibition rate is 70% or more and less than 90%.
- ⁇ Cytotoxicity inhibition rate is 50% or more and less than 70%.
- X Cytotoxicity inhibition rate is less than 50%.
- the solution was diluted 10-fold with physiological saline four times and smeared on a blood agar plate using a spiral plater.
- a mixture of physiological saline and bacterial solution at 1: 1 (volume ratio) instead of the drug was used.
- the blood plate was cultured at 37 ° C. under anaerobic conditions (95 vol% nitrogen, 5 vol% carbon dioxide) for 5 days, and the number of colonies formed was counted.
- Evaluation criteria for bactericidal effect in oral cavity A: The viable cell rate is less than 10% compared to the control. A: The viable cell rate is 10% to less than 40% compared to the control. B: The viable cell rate is 40% to less than 80% compared to the control. More than 80% viable bacteria compared to control
Abstract
Description
従って、歯周炎等の歯周病の予防、治療には、口腔内の歯周病原因菌の殺菌と共に、上記のような口腔内の細胞傷害を抑制することが有効であると考えられており、両効果を兼ね備えた口腔用組成物を与える技術の開発が望まれる。 Periodontal disease is an infection caused by bacteria, mainly anaerobic gram-negative bacteria such as Porphyromonas gingivalis, and exotoxins (such as leukotoxin) and endotoxins (such as lipopolysaccharide) produced by the bacteria. ) Induces inflammation and damages the tissue. On the other hand, in the living body, neutrophils and lymphocytes infiltrate the periodontal pockets and gingival tissues, phagocytosing bacteria, and creating an immune response that eliminates these foreign substances by creating specific antibodies, In recent years, it has been pointed out that active oxygen generated excessively during phagocytosis further damages biological tissues. For example, when fibroblasts constituting the gingiva are injured by active oxygen, collagen fibers are destroyed and the cell growth ability is reduced, so that the gingiva is retracted and periodontal disease progresses.
Therefore, for the prevention and treatment of periodontal diseases such as periodontitis, it is considered effective to suppress oral cavity cell damage as described above in addition to sterilization of periodontal disease-causing bacteria in the oral cavity. Therefore, development of a technique for providing an oral composition having both effects is desired.
しかしながら、ヒトディフェンシンは、歯周病原性細菌に対する殺菌効果が十分とは言い難く、殺菌力の向上が課題となっていた。 Regarding sterilization of periodontopathic bacteria in the oral cavity, human defensin, a host-derived peptide, is known to have antibacterial action against a wide range of oral pathogenic bacteria and is safe for the human body. In Patent Document 1 (Japanese Patent Laid-Open No. 2001-288105), human β-defensin has a strong antibacterial activity against a periodontitis-causing fungus, Actinobacillus actinomycetemcomitans, and Porphyromonas gingivalis It is disclosed that periodontitis-causing bacteria such as (Porphyromonas gingivalis) also have antibacterial activity, and a human β-defensin-containing dentifrice has been proposed. Patent Document 2 (Japanese Patent Laid-Open No. 2009-155214) proposes a composition for oral cavity in which the antibacterial effect of oral biofilm is improved by using human defensin and dextranase in combination.
However, human defensins cannot be said to have a sufficient bactericidal effect on periodontopathic bacteria, and improvement of bactericidal power has been a problem.
〔1〕
(A)ヒトディフェンシンと、(B)アスコルビン酸エステル又はその塩とを含有してなることを特徴とする口腔用組成物。
〔2〕
(A)成分が、ヒトディフェンシンβ-2又はヒトディフェンシンβ-3である〔1〕に記載の口腔用組成物。
〔3〕
(B)成分が、アスコルビン酸リン酸エステル及びその塩、アスコルビン酸硫酸エステル及びその塩から選ばれる1種以上である〔1〕又は〔2〕に記載の口腔用組成物。
〔4〕
(B)成分が、アスコルビン酸リン酸エステルマグネシウム及び/又はアスコルビン酸リン酸エステルナトリウムである〔3〕に記載の口腔用組成物。
〔5〕
(A)成分を0.000005~0.0005質量%、(B)成分を0.1~2質量%含有する〔1〕~〔4〕のいずれかに記載の口腔用組成物。
〔6〕
(A)成分に対して(B)成分が質量比で200~400,000倍量である〔1〕~〔5〕のいずれかに記載の口腔用組成物。
〔7〕
歯磨剤又は洗口剤である〔1〕~〔6〕のいずれかに記載の口腔用組成物。
〔8〕
歯周病予防又は治療用である〔1〕~〔7〕のいずれかに記載の口腔用組成物。 Accordingly, the present invention provides the following oral composition.
[1]
An oral composition comprising (A) human defensin and (B) an ascorbic acid ester or a salt thereof.
[2]
The composition for oral cavity according to [1], wherein the component (A) is human defensin β-2 or human defensin β-3.
[3]
(B) The composition for oral cavity as described in [1] or [2] whose component is 1 or more types chosen from ascorbic-acid phosphate and its salt, ascorbic-acid sulfate, and its salt.
[4]
The composition for oral cavity according to [3], wherein the component (B) is magnesium ascorbate phosphate and / or sodium ascorbate phosphate.
[5]
The oral composition according to any one of [1] to [4], which comprises 0.000005 to 0.0005 mass% of component (A) and 0.1 to 2 mass% of component (B).
[6]
The oral composition according to any one of [1] to [5], wherein the component (B) is 200 to 400,000 times the mass of the component (A).
[7]
The oral composition according to any one of [1] to [6], which is a dentifrice or mouthwash.
[8]
The oral composition according to any one of [1] to [7], which is used for prevention or treatment of periodontal disease.
ヒトディフェンシンは市販品を使用することができ、例えばペプチド研究所社製のヒトディフェンシンβ-2、Anygen社製のヒトディフェンシンβ-3が挙げられる。 (A) Human defensin includes human defensin α, human defensin β-1, human defensin β-2, and human defensin β-3, and one or more types selected from these are used. However, human defensin β-2 and human defensin β-3 are particularly preferable in terms of the bactericidal effect of periodontal disease-causing bacteria.
A commercially available human defensin can be used, and examples thereof include human defensin β-2 manufactured by Peptide Institute, and human defensin β-3 manufactured by Anygen.
アスコルビン酸エステル又はその塩としては、特にアスコルビン酸リン酸エステル又はその塩、アスコルビン酸硫酸エステル又はその塩が好ましい。アスコルビン酸リン酸エステル、アスコルビン酸硫酸エステルは、アスコルビン酸の2,3,5,6位のいずれかの水酸基の1つ又は2つ以上がリン酸、ポリリン酸等のリン酸化合物又は硫酸のエステルとなったものであり、具体的には、アスコルビン酸-2-リン酸エステル、アスコルビン酸-3-リン酸エステル、アスコルビン酸-6-リン酸エステル、アスコルビン酸-2-ポリリン酸エステル、アスコルビン酸-2-硫酸エステルが挙げられる。その塩としては、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩等のアルカリ金属塩、アルカリ土類金属塩が挙げられる。(B)成分としては、これらから選ばれる1種又は2種以上を使用できるが、特に口腔用として用いるものであり、歯肉炎予防効果、とりわけ細胞傷害抑制効果の点から、アスコルビン酸リン酸エステルのマグネシウム塩、ナトリウム塩が好適に用いられる。 Ascorbic acid ester of component (B), one or more of hydroxyl groups at any of positions 2, 3, 5, and 6 of ascorbic acid is phosphoric acid, polyphosphoric acid, sulfuric acid, fatty acid, or other pharmaceutically acceptable. This is an ester of a compound.
As the ascorbic acid ester or a salt thereof, an ascorbic acid phosphate or a salt thereof, or an ascorbic acid sulfate or a salt thereof is particularly preferable. Ascorbic acid phosphoric acid ester and ascorbic acid sulfuric acid ester are phosphoric acid compounds such as phosphoric acid and polyphosphoric acid, or an ester of sulfuric acid. Specifically, ascorbic acid-2-phosphate, ascorbic acid-3-phosphate, ascorbic acid-6-phosphate, ascorbic acid-2-polyphosphate, ascorbic acid -2-Sulfate ester. Examples of the salt include alkali metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and alkaline earth metal salts. As the component (B), one or more selected from these can be used. Particularly, it is used for the oral cavity, and is an ascorbic acid phosphate ester from the viewpoint of a gingivitis preventing effect, particularly a cytotoxicity suppressing effect. The magnesium salt and sodium salt are preferably used.
アニオン性界面活性剤としては、ラウリル硫酸ナトリウム等のアルキル硫酸塩、N-ラウロイルサルコシンナトリウム、N-ミリストイルサルコシンナトリウム等のN-アシルサルコシン酸塩、N-パルミトイルグルタミン酸ナトリウム等のN-アシルグルタミン酸塩、N-メチル-N-アシルタウリンナトリウム、N-メチル-N-アシルアラニンナトリウム、α-オレフィンスルホン酸ナトリウムなどが挙げられる。
ノニオン性界面活性剤としては、ショ糖脂肪酸エステル、マルトース脂肪酸エステル等の糖脂肪酸エステル、マルチトール脂肪酸エステル、ラクチトール脂肪酸エステル等の糖アルコール脂肪酸エステル、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、モノラウリン酸ヘキサグリセリル、モノミリスチン酸ヘキサグリセリル、モノラウリン酸デカグリセリル、モノミリスチン酸デカグリセリル等のポリグリセリン脂肪酸エステル、ポリオキシエチレンソルビタンモノラウレート、ポリオキシエチレンソルビタンモノステアレート等のポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油等のポリオキシエチレン脂肪酸エステル、ポリオキシエチレンラウリルエーテル等のポリオキシエチレン高級アルコールエーテル、ラウリン酸ジエタノールアミド等の脂肪酸アルカノールアミド、ポリオキシエチレンポリオキシプロピレン共重合体、ポリオキシエチレンポリオキシプロピレン脂肪酸エステルなどが挙げられる。
カチオン性界面活性剤としては、アルキルアンモニウム、アルキルベンジルアンモニウム塩など、両性界面活性剤としては、アルキルベタイン、脂肪酸アミドプロピルベタイン、アルキルイミダゾリニウムベタイン等のベタイン系などが挙げられる。
界面活性剤の配合量は、組成物全体の0.001~10%、特に0.1~5%が好ましい。 As the surfactant, an anionic surfactant, a nonionic surfactant, a cationic surfactant, and an amphoteric surfactant can be blended.
Examples of the anionic surfactant include alkyl sulfates such as sodium lauryl sulfate, N-acyl sarcosine salts such as N-lauroyl sarcosine sodium and N-myristoyl sarcosine sodium, N-acyl glutamates such as sodium N-palmitoyl glutamate, Examples include sodium N-methyl-N-acyl taurine, sodium N-methyl-N-acylalanine, sodium α-olefin sulfonate, and the like.
Nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters and maltose fatty acid esters, sugar alcohol fatty acid esters such as maltitol fatty acid esters and lactitol fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, hexaglyceryl monolaurate, Polyglycerin fatty acid esters such as hexaglyceryl monomyristate, decaglyceryl monolaurate, decaglyceryl monomyristic acid, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene Polyoxyethylene fatty acid esters such as hydrogenated castor oil and polyoxyethylene higher alcohols such as polyoxyethylene lauryl ether Ethers, fatty acid alkanolamides, such as lauric acid diethanolamide, polyoxyethylene polyoxypropylene copolymers, polyoxyethylene polyoxypropylene fatty acid esters.
Examples of the cationic surfactant include alkyl ammonium and alkyl benzyl ammonium salts, and examples of the amphoteric surfactant include betaines such as alkyl betaines, fatty acid amidopropyl betaines, and alkyl imidazolinium betaines.
The blending amount of the surfactant is preferably 0.001 to 10%, particularly preferably 0.1 to 5% of the entire composition.
また、配合量も特に限定されないが、上記の香料素材は、製剤組成中に0.000001~1%使用するのが好ましい。また、上記香料素材を使用した賦香用香料としては、製剤組成中に0.1~2%使用するのが好ましい。 Perfumes include peppermint oil, spearmint oil, anise oil, eucalyptus oil, winter green oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, Lime oil, lavender oil, rosemary oil, laurel oil, camomil oil, caraway oil, marjoram oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie Natural fragrances such as oil, coconut oil, Iris concrete, absolute peppermint, absolute rose, orange flower, and processing of these natural fragrances (front reservoir cut, rear reservoir cut, fractional distillation, liquid-liquid extraction, essence, Powdered fragrance etc.) and menthol Carvone, Anethole, Cineol, Methyl salicylate, Synamic aldehyde, Eugenol, 3-l-Mentoxypropane-1,2-diol, Thymol, Linalol, Linarel acetate, Limonene, Menthone, Menthyl acetate, N-Substituted-paramenthane 3-carboxamide, pinene, octylaldehyde, citral, pulegone, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate, allylcyclohexane propionate, methyl anthranilate, ethyl methyl phenyl glycidate, vanillin, undecalactone, Hexanal, butanol, isoamyl alcohol, hexenol, dimethyl sulfide, cycloten, furfural, trimethylpyrazine, ethyl lactate, ethyl Oral compositions such as single flavors such as thioacetate, and other flavors such as strawberry flavor, apple flavor, banana flavor, pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, fruit mix flavor, tropical fruit flavor, etc. It can be used in combination with known perfume materials used in the above.
Further, the blending amount is not particularly limited, but the above fragrance material is preferably used at 0.000001 to 1% in the preparation composition. Further, as the flavoring fragrance using the fragrance material, it is preferable to use 0.1 to 2% in the preparation composition.
防腐剤としては、パラオキシ安息香酸エステル、安息香酸ナトリウム等の安息香酸又はその塩などが挙げられる。 Examples of the sweetener include saccharin sodium, stevioside, paramethoxycinnamic aldehyde, perilartin and the like. Examples of the colorant include blue No. 1, yellow No. 4, titanium dioxide and the like.
Examples of the preservative include benzoic acid such as paraoxybenzoic acid ester and sodium benzoate, or a salt thereof.
表1に示す組成の試料溶液を常法により調製し、下記実験例に示す方法で細胞傷害抑制効果、口腔内細菌殺菌効果を評価した。結果を表に併記した。 [Examples and Comparative Examples]
A sample solution having the composition shown in Table 1 was prepared by a conventional method, and the cytotoxicity-inhibiting effect and the oral bacterial bactericidal effect were evaluated by the methods shown in the following experimental examples. The results are shown in the table.
市販の歯肉線維芽細胞Gin-1(DSファーマバイオメディカル社製)を10%牛胎児血清(FBS)含有Dullbecco’s Modified Eagle Medium(D-MEM)中で、37℃、5%CO2の条件下で前培養した。5×104cells/mLに調製したGin-1を48ウェルプレートに400μL播種し、さらに24時間培養した。培養液を除去後、表に示した試料溶液をそれぞれ400μL添加(10%FBS含有D-MEMで20倍希釈)して48時間、薬剤処置した。
処置終了後、1mMの過酸化水素水溶液(活性酸素を想定)を60分間添加した。処置終了後、試料溶液を除去し、1mMの過酸化水素を含む溶液(10%FBS含有D-MEM)を400μL添加し、60分間処置した。溶液を除去後、細胞活性試薬(Calcein AM;インビトロジェン社製)を200μL添加し、37℃、5%CO2条件下で30分間インキュベートした。その後、プレートリーダー(Fluoroskan Ascent;Labsystems社製)を用いて、Ex/Em=485nm/538nmの条件下で蛍光強度を測定した。
下記計算式(1)から算出した結果を細胞傷害抑制率とした。細胞傷害抑制試験はn=10で実施した。平均値を算出し、下記の評点基準で細胞傷害抑制効果を評価した。
細胞傷害抑制率(%)=(試料溶液処置後に過酸化水素処置した場合の蛍光強度)/(試料溶液処置後に過酸化水素無処置の場合の蛍光強度)×100 …(1) <Experimental Example 1> Cytotoxicity inhibitory effect test A commercially available gingival fibroblast Gin-1 (manufactured by DS Pharma Biomedical Co., Ltd.) was used in a 10% fetal bovine serum (FBS) -containing Dulbecco's Modified Eagle Medium (D-MEM). And 37 ° C. and 5% CO 2 . 400 μL of Gin-1 prepared to 5 × 10 4 cells / mL was seeded in a 48-well plate and further cultured for 24 hours. After removing the culture solution, 400 μL of each sample solution shown in the table was added (diluted 20-fold with D-MEM containing 10% FBS) and treated with drugs for 48 hours.
After the treatment was completed, a 1 mM hydrogen peroxide aqueous solution (assuming active oxygen) was added for 60 minutes. After completion of the treatment, the sample solution was removed, and 400 μL of a solution containing 1 mM hydrogen peroxide (D-MEM containing 10% FBS) was added and treated for 60 minutes. After removing the solution, 200 μL of a cell activity reagent (Calcinin AM; manufactured by Invitrogen) was added and incubated at 37 ° C. under 5% CO 2 for 30 minutes. Thereafter, the fluorescence intensity was measured under conditions of Ex / Em = 485 nm / 538 nm using a plate reader (Fluoroskan Ascent; manufactured by Labsystems).
The result calculated from the following formula (1) was taken as the cytotoxicity inhibition rate. Cytotoxicity inhibition test was performed at n = 10. The average value was calculated, and the cytotoxicity-inhibiting effect was evaluated based on the following criteria.
Cytotoxicity inhibition rate (%) = (fluorescence intensity when treated with hydrogen peroxide after treatment with sample solution) / (fluorescence intensity when treated with no hydrogen peroxide after treatment with sample solution) × 100 (1)
◎:細胞傷害抑制率が90%以上
○:細胞傷害抑制率が70%以上90%未満
△:細胞傷害抑制率が50%以上70%未満
×:細胞傷害抑制率が50%未満 Criteria for evaluation of cytostatic effect;
A: Cytotoxicity inhibition rate is 90% or more. O: Cytotoxicity inhibition rate is 70% or more and less than 90%. Δ: Cytotoxicity inhibition rate is 50% or more and less than 70%. X: Cytotoxicity inhibition rate is less than 50%.
ヘミン(和光純薬工業(株)製、500μg/mL)、メナジオン(和光純薬工業(株)製、100μg/mL)を添加したトッド・ヒューイット・ブロス(日本ベクトンディッキンソン社製)で前培養したポルフィロモナス ジンジバリス ATCC33277株を生理食塩水で1×109個/mLになるように菌の浮遊液を調製した。当菌液と表に示した試料溶液を1:1(容量比)で混合し、3分間静置した。その後、生理食塩水で10倍ずつ4段階希釈を行い、スパイラルプレーターにて血液寒天平板に塗抹した。対照として薬剤の代わりに生理食塩水と菌液を1:1(容量比)で混合したものを用いた。
血液平板を37℃、嫌気条件(95vol%窒素、5vol%二酸化炭素)下で5日間培養し、形成したコロニー数を計測した。この口腔内細菌殺菌試験はn=5で実施した。平均値を算出し、対照溶液のコロニー数に対する試料溶液のコロニー数を生菌率として求め、下記基準に基づき口腔内細菌殺菌効果を評価した。 <Experimental example 2> Oral bacteria bactericidal effect test Todd Hewitt broth added with hemin (manufactured by Wako Pure Chemical Industries, Ltd., 500 μg / mL) and menadione (manufactured by Wako Pure Chemical Industries, Ltd., 100 μg / mL) A suspension of fungi was prepared from Porphyromonas gingivalis strain ATCC33277 pre-cultured with Nippon Becton Dickinson Co., Ltd. at 1 × 10 9 cells / mL with physiological saline. The bacterial solution and the sample solution shown in the table were mixed at 1: 1 (volume ratio) and allowed to stand for 3 minutes. Thereafter, the solution was diluted 10-fold with physiological saline four times and smeared on a blood agar plate using a spiral plater. As a control, a mixture of physiological saline and bacterial solution at 1: 1 (volume ratio) instead of the drug was used.
The blood plate was cultured at 37 ° C. under anaerobic conditions (95 vol% nitrogen, 5 vol% carbon dioxide) for 5 days, and the number of colonies formed was counted. This oral bacteria sterilization test was conducted with n = 5. The average value was calculated, the number of colonies in the sample solution relative to the number of colonies in the control solution was determined as the viable cell rate, and the bactericidal effect in the oral cavity was evaluated based on the following criteria.
◎:対照と比較して生菌率が10%未満
○:対照と比較して生菌率が10%~40%未満
△:対照と比較して生菌率が40%~80%未満
×:対照と比較して生菌率が80%以上 Evaluation criteria for bactericidal effect in oral cavity;
A: The viable cell rate is less than 10% compared to the control. A: The viable cell rate is 10% to less than 40% compared to the control. B: The viable cell rate is 40% to less than 80% compared to the control. More than 80% viable bacteria compared to control
(A)ヒトディフェンシン(ヒトディフェンシンβ-2、ペプチド研究所社製)
(B)アスコルビン酸-2-リン酸エステルマグネシウム(和光純薬工業(株)製)
(B)アスコルビン酸-2-リン酸エステルナトリウム(和光純薬工業(株)製)
(B)アスコルビン酸-2-硫酸エステルナトリウム(和光純薬工業(株)製)
アスコルビン酸ナトリウム(和光純薬工業(株)製)
ヒスタチン5(和光純薬工業(株)製) Details of the raw materials used are shown below.
(A) Human defensin (Human defensin β-2, manufactured by Peptide Institute, Inc.)
(B) Ascorbic acid-2-phosphate magnesium (manufactured by Wako Pure Chemical Industries, Ltd.)
(B) Sodium ascorbate-2-phosphate (manufactured by Wako Pure Chemical Industries, Ltd.)
(B) Sodium ascorbyl-2-sulfate (manufactured by Wako Pure Chemical Industries, Ltd.)
Sodium ascorbate (manufactured by Wako Pure Chemical Industries, Ltd.)
Histatin 5 (manufactured by Wako Pure Chemical Industries, Ltd.)
(A)ヒトディフェンシンβ-2(ペプチド研究所社製)0.00001%
(B)アスコルビン酸-2-リン酸エステルマグネシウム
(和光純薬工業(株)製) 0.5
無水ケイ酸 20.0
ラウリル硫酸ナトリウム 1.0
プロピレングリコール 3.0
ソルビット液(100%品) 30.0
キサンタンガム 1.0
サッカリンナトリウム 0.1
香料 1.0
精製水 バランス
合計 100.0% [Prescription Example 1] Toothpaste (A) Human defensin β-2 (Peptide Institute, Inc.) 0.00001%
(B) Magnesium ascorbyl 2-phosphate ester (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5
Silicic anhydride 20.0
Sodium lauryl sulfate 1.0
Propylene glycol 3.0
Sorbit liquid (100% product) 30.0
Xanthan gum 1.0
Saccharin sodium 0.1
Fragrance 1.0
Purified water balance <br/> Total 100.0%
(A)ヒトディフェンシンβ-3(Anygen社製) 0.0005%
(B)アスコルビン酸-2-リン酸エステルマグネシウム
(和光純薬工業(株)製) 0.5
キシリトール 3.0
グリセリン(AI=100) 2.0
ポリオキシエチレン(60)硬化ヒマシ油
(HCO-60) 0.5
クエン酸ナトリウム 0.3
クエン酸 0.1
安息香酸ナトリウム 0.3
安息香酸メチル 0.1
香料 0.2
サッカリンナトリウム 0.002
プロピレングリコール 3.0
ポリエチレングリコール 5.0
精製水 バランス
合計 100.0% [Prescription Example 2] Liquid dentifrice (A) Human defensin β-3 (Anygen) 0.0005%
(B) Magnesium ascorbyl 2-phosphate ester (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5
Xylitol 3.0
Glycerin (AI = 100) 2.0
Polyoxyethylene (60) hydrogenated castor oil (HCO-60) 0.5
Sodium citrate 0.3
Citric acid 0.1
Sodium benzoate 0.3
Methyl benzoate 0.1
Fragrance 0.2
Saccharin sodium 0.002
Propylene glycol 3.0
Polyethylene glycol 5.0
Purified water balance <br/> Total 100.0%
(A)ヒトディフェンシンβ-2(ペプチド研究所社製)0.0001%
(B)アスコルビン酸-2-リン酸エステルマグネシウム
(和光純薬工業(株)製) 0.5
キシリトール 3.0
グリセリン(100%品) 5.0
ポリオキシエチレン(60)硬化ヒマシ油
(HCO-60) 0.5
クエン酸ナトリウム 0.3
クエン酸 0.1
香料 0.2
エタノール 8.0
プロピレングリコール 3.0
精製水 バランス
合計 100.0% [Prescription Example 3] Liquid Dentifrice (A) Human Defensin β-2 (Peptide Institute, Inc.) 0.0001%
(B) Magnesium ascorbyl 2-phosphate ester (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5
Xylitol 3.0
Glycerin (100% product) 5.0
Polyoxyethylene (60) hydrogenated castor oil (HCO-60) 0.5
Sodium citrate 0.3
Citric acid 0.1
Fragrance 0.2
Ethanol 8.0
Propylene glycol 3.0
Purified water balance <br/> Total 100.0%
Claims (8)
- (A)ヒトディフェンシンと、(B)アスコルビン酸エステル又はその塩とを含有してなることを特徴とする口腔用組成物。 An oral composition comprising (A) human defensin and (B) ascorbic acid ester or a salt thereof.
- (A)成分が、ヒトディフェンシンβ-2又はヒトディフェンシンβ-3である請求項1記載の口腔用組成物。 The composition for oral cavity according to claim 1, wherein the component (A) is human defensin β-2 or human defensin β-3.
- (B)成分が、アスコルビン酸リン酸エステル及びその塩、アスコルビン酸硫酸エステル及びその塩から選ばれる1種以上である請求項1又は2記載の口腔用組成物。 The composition for oral cavity according to claim 1 or 2, wherein the component (B) is at least one selected from ascorbic acid phosphate and salts thereof, ascorbic acid sulfate and salts thereof.
- (B)成分が、アスコルビン酸リン酸エステルマグネシウム及び/又はアスコルビン酸リン酸エステルナトリウムである請求項3記載の口腔用組成物。 The composition for oral cavity according to claim 3, wherein the component (B) is magnesium ascorbate phosphate and / or sodium ascorbate phosphate.
- (A)成分を0.000005~0.0005質量%、(B)成分を0.1~2質量%含有する請求項1乃至4のいずれか1項記載の口腔用組成物。 The composition for oral cavity according to any one of claims 1 to 4, comprising 0.000005 to 0.0005 mass% of component (A) and 0.1 to 2 mass% of component (B).
- (A)成分に対して(B)成分が質量比で200~400,000倍量である請求項1乃至5のいずれか1項記載の口腔用組成物。 The composition for oral cavity according to any one of claims 1 to 5, wherein the component (B) is 200 to 400,000 times the mass ratio of the component (A).
- 歯磨剤又は洗口剤である請求項1乃至6のいずれか1項記載の口腔用組成物。 The composition for oral cavity according to any one of claims 1 to 6, which is a dentifrice or a mouthwash.
- 歯周病予防又は治療用である請求項1乃至7のいずれか1項記載の口腔用組成物。 The composition for oral cavity according to any one of claims 1 to 7, which is used for prevention or treatment of periodontal disease.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480009052.3A CN104994835B (en) | 2013-02-14 | 2014-02-05 | Composition for oral cavity |
KR1020157021957A KR20150118144A (en) | 2013-02-14 | 2014-02-05 | Oral composition |
JP2015500204A JP6222217B2 (en) | 2013-02-14 | 2014-02-05 | Oral composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-026574 | 2013-02-14 | ||
JP2013026574 | 2013-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014125977A1 true WO2014125977A1 (en) | 2014-08-21 |
Family
ID=51353984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/052676 WO2014125977A1 (en) | 2013-02-14 | 2014-02-05 | Oral composition |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6222217B2 (en) |
KR (1) | KR20150118144A (en) |
CN (1) | CN104994835B (en) |
WO (1) | WO2014125977A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001288105A (en) * | 2000-04-05 | 2001-10-16 | Yoshihiro Abiko | Medicine for periodontitis |
WO2005027893A1 (en) * | 2003-09-19 | 2005-03-31 | Otsuka Pharmaceutical Co., Ltd. | HUMAN β-DEFENSIN SECRETION PROMOTER |
JP2009155214A (en) * | 2007-12-25 | 2009-07-16 | Lion Corp | Composition for oral cavity |
JP2012180330A (en) * | 2011-03-03 | 2012-09-20 | Lion Corp | Composition for oral cavity and inhibitor of damage in gingival fibroblast caused by active oxygen |
-
2014
- 2014-02-05 KR KR1020157021957A patent/KR20150118144A/en not_active Application Discontinuation
- 2014-02-05 JP JP2015500204A patent/JP6222217B2/en not_active Expired - Fee Related
- 2014-02-05 WO PCT/JP2014/052676 patent/WO2014125977A1/en active Application Filing
- 2014-02-05 CN CN201480009052.3A patent/CN104994835B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001288105A (en) * | 2000-04-05 | 2001-10-16 | Yoshihiro Abiko | Medicine for periodontitis |
WO2005027893A1 (en) * | 2003-09-19 | 2005-03-31 | Otsuka Pharmaceutical Co., Ltd. | HUMAN β-DEFENSIN SECRETION PROMOTER |
JP2009155214A (en) * | 2007-12-25 | 2009-07-16 | Lion Corp | Composition for oral cavity |
JP2012180330A (en) * | 2011-03-03 | 2012-09-20 | Lion Corp | Composition for oral cavity and inhibitor of damage in gingival fibroblast caused by active oxygen |
Also Published As
Publication number | Publication date |
---|---|
CN104994835B (en) | 2017-09-01 |
KR20150118144A (en) | 2015-10-21 |
CN104994835A (en) | 2015-10-21 |
JP6222217B2 (en) | 2017-11-01 |
JPWO2014125977A1 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6207541B2 (en) | Oral composition | |
JP5041135B2 (en) | Oral composition and oral biofilm formation inhibitor | |
JP5862195B2 (en) | Oral composition and oral biofilm disinfectant | |
JP5552725B2 (en) | Oral composition and oral biofilm disinfectant | |
CN111356440A (en) | Oral biofilm formation inhibitor and oral composition | |
JP2009149535A (en) | Oral composition | |
JP2008156288A (en) | Composition for oral cavity | |
JP5644591B2 (en) | Oral composition and inhibitor of active oxygen injury of gingival fibroblasts | |
JP2010241693A (en) | Composition for oral cavity | |
JP5471335B2 (en) | Oral biofilm disinfectant | |
JP2005047855A (en) | Oral cavity biofilm inhibitor and composition for oral cavity | |
JP2007169201A (en) | Composition for oral cavity | |
JP7445910B2 (en) | Oral compositions, oral care products, and foods containing oral resident bacteria regulators | |
JP6222216B2 (en) | Oral composition | |
JP4133796B2 (en) | Oral biofilm suppression composition | |
JP4883268B2 (en) | Oral composition and oral biofilm inhibitor | |
JP2003246717A (en) | Composition for oral cavity | |
JP6222217B2 (en) | Oral composition | |
JP2017007991A (en) | Composition for oral cavity and method for improving bactericidal activity of hinokitiol in the composition | |
JP2017007993A (en) | Oral cavity composition and oral cavity biofilm fungicide | |
JP4888636B2 (en) | Dentifrice composition | |
JP2006176416A (en) | Composition for oral cavity | |
JP2006124315A (en) | Oral composition | |
JP5720697B2 (en) | Dentifrice composition | |
JP6011250B2 (en) | Oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14751930 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015500204 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201504711 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 20157021957 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14751930 Country of ref document: EP Kind code of ref document: A1 |